Cronos Group Inc. (CRON)

14.96
0.03 0.20
NASDAQ : Health Technology
Prev Close 14.99
Open 14.98
Day Low/High 14.63 / 15.01
52 Wk Low/High 5.61 / 25.10
Volume 1.93M
Avg Volume 4.89M
Exchange NASDAQ
Shares Outstanding 334.09M
Market Cap 5.02B
EPS -0.10
P/E Ratio 39.32
Div & Yield N.A. (N.A)

Latest News

Cronos Rises After Announcing Acquisition of Winnipeg Fermentation Plant

Cronos Rises After Announcing Acquisition of Winnipeg Fermentation Plant

Cronos will acquire an 84,000-square-foot fermentation and manufacturing facility.

Morningstar High on Pot Growth, Sees U.S. Going Legal by 2023

Morningstar High on Pot Growth, Sees U.S. Going Legal by 2023

Analysts say nation will turn a new leaf, changing federal law within a few years, as cannabis industry expected to grow big time over next decade.

Would You Rather Have an Executive Team Managing the Company or the Stock Price?

Would You Rather Have an Executive Team Managing the Company or the Stock Price?

It all comes down to matching my time frame.

Canopy Growth Turmoil and Why It Matters to Us

Aurora Cannabis is currently the portfolio's second best performer.

OrganiGram Could Climb Higher, but You Need Discipline Before Buying

OrganiGram Could Climb Higher, but You Need Discipline Before Buying

Here's how to play OGI stock right now.

Too Many Bulls?: Cramer's 'Mad Money' Recap (Tuesday 7/2/19)

Too Many Bulls?: Cramer's 'Mad Money' Recap (Tuesday 7/2/19)

What are we too bullish about, asks Jim Cramer? Depending on the sector, investors have good reason to be optimistic.

PepsiCo, Blackstone, Grocery Outlet: 'Mad Money' Lightning Round

PepsiCo, Blackstone, Grocery Outlet: 'Mad Money' Lightning Round

Jim Cramer takes a look at PepsiCo, Blackstone, Grocery Outlet Holding Corp. Mastec, International Paper, Arrowhead Pharma, Organigram Holdings and more.

5 Cannabis ETFs to Fire Up Your Portfolio

5 Cannabis ETFs to Fire Up Your Portfolio

Two of them are brand new.

Prohibition and the Paradoxical Proclivity of Cannabis Consumption

Prohibition and the Paradoxical Proclivity of Cannabis Consumption

Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?

This Is Canopy Growth's Must-Hold Support Level

This Is Canopy Growth's Must-Hold Support Level

Canopy Growth stock is taking a beating on Friday after the company disappointed investors with its quarterly results. Here's the must-hold support level for the stock now.

Should Investors Buy the Dip in Canopy Growth Stock?

Should Investors Buy the Dip in Canopy Growth Stock?

Canopy's earnings losses could just be a stepping stone to becoming the industry leader.

Young Folks Are High on a Current Name, and We Plug Another Into the Bullpen

An investing app indicates Aurora Cannabis is popular with young investors, while we also intend to monitor alternative energy firm Plug Power.

Tilray Is Tough to Trade as It Breaks Out of a Nasty Downtrend

Tilray Is Tough to Trade as It Breaks Out of a Nasty Downtrend

Tilray is erupting higher and breaking over downtrend resistance. It's been a long time coming for this troubled cannabis stock.

Cronos Jumps on Double Upgrade, Tilray Initiated With Perform Rating

Cronos Jumps on Double Upgrade, Tilray Initiated With Perform Rating

Bank of America lifts its price target on Cronos to $20 from $13.

Cannabis Stocks Lower as FDA Hearing on CBD-Infused Foods Gets Underway

Cannabis Stocks Lower as FDA Hearing on CBD-Infused Foods Gets Underway

The FDA will discuss the safety and product quality of CBD-derived compounds in a public hearing Friday.

Ben & Jerry's Wants to Get in on CBD Craze

Ben & Jerry's Wants to Get in on CBD Craze

The company's announcement comes ahead of an FDA's public hearing on the legalization of CBD-infused foods and beverages on Friday.

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.

Trimming a Position and What to Make of an Earnings Report

Energy Recovery has stabilized above our target, warranting some action. Plus, Aurora Cannabis reports earnings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRON, SFS, TCS, TDW, TPRE Downgrades: AMBC, CARG, IRM, MUR, PEGI, RDFN, RL, TBI Initiations: RDVT Read on to get TheStreet Quant Ratings' detailed report:

Cronos Climbs After Securing Private Label Concentrate Agreement With MediPharm

Cronos Climbs After Securing Private Label Concentrate Agreement With MediPharm

Cronos announces that it has entered into a multi-year private label cannabis concentrate supply agreement MediPharm Labs.

Stocks Spring Back: Cramer's 'Mad Money' Recap (Friday 5/10/19)

Stocks Spring Back: Cramer's 'Mad Money' Recap (Friday 5/10/19)

The markets staged a big reversal Friday after the China tariffs and Uber's IPO thud. Jim Cramer's got your game plan for next week.

ADT, Domo, Aurora Cannabis: 'Mad Money' Lightning Round

ADT, Domo, Aurora Cannabis: 'Mad Money' Lightning Round

Jim Cramer takes a look at ADT, Domo, Aurora Cannabis, Seaspan, Walgreens Boots Alliance, Sirius XM Radio and more.

Cronos Falls Despite Swinging to Small First-Quarter Profit

Cronos Falls Despite Swinging to Small First-Quarter Profit

Cronos shares are falling despite easily topping analysts' earnings estimates.

Ask Cramer: Cannabis ETF vs. Individual Stock: Which to Buy?

Ask Cramer: Cannabis ETF vs. Individual Stock: Which to Buy?

Should you buy cannabis ETF instead of attempting to pick an individual stock?

Altria Shares Fall After Tobacco Maker Misses Earnings Estimates

Altria Shares Fall After Tobacco Maker Misses Earnings Estimates

The tobacco maker misses expectations in the first quarter on both the top and bottom lines. It reiterates 2019 earnings guidance.

Toke'n Economy: Pot Stock Investment Advice For 4/20 Weekend

Toke'n Economy: Pot Stock Investment Advice For 4/20 Weekend

Pot stocks may have cooled off in recent months but the industry is still hot and Bank of America Merrill Lynch expects it to get hotter as it reaches maturity.

Jim Cramer: It's 420, Here's How to Play the Cannabis Sector

Jim Cramer: It's 420, Here's How to Play the Cannabis Sector

It's 420. TheStreet's Jim Cramer discusses Canopy Growth, Tilray, Constellation Brands and other investing opportunities in the cannabis sector!

Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space

Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space

CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.

TheStreet Quant Rating: C+ (Hold)